GlassScriptPhysician profile
Jennifer Mabry
NPI 1649803081
$4,531.88
in general payments reported to CMS, 2019-2025
33 companies · $997 in 2025
The $997 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $429 · 2022: $892 · 2023: $1,114 · 2024: $1,099 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,210.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $841.43 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $417.59 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $368.90 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $311.80 | 2021-2025 | Airsupra, Breztri, Tezspire |
| Pfizer INC. | $287.57 | 2021-2025 | |
| Novo Nordisk INC | $280.35 | 2021-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.76 | 2021-2025 | Jardiance |
| Amgen INC. | $249.94 | 2021-2025 | Repatha, Otezla, Evenity |
| Boston Scientific Corporation | $165.67 | 2022-2023 | Watchman Access System |
| Biosense Webster, INC. | $146.52 | 2024 | Carto 3 |
| Sanofi-Aventis U.S. LLC | $146.14 | 2021-2024 | |
| Exact Sciences Corporation | $141.63 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $129.02 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Actelion Pharmaceuticals US, INC. | $128.70 | 2022 | |
| Novartis Pharmaceuticals Corporation | $109.19 | 2022-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $56.91 | 2023-2025 | |
| Amarin Pharma, INC. | $52.07 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $46.62 | 2024 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $42.15 | 2024-2025 | Voquezna |
| Abbott Laboratories | $36.43 | 2025 | Freestyle Libre 3 |
| Dexcom, INC. | $35.80 | 2025 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $33.47 | 2025 | Yeztugo |
| Sumitomo Pharma America, INC. | $31.20 | 2025 | Gemtesa |
| Dynavax Technologies Corporation | $27.99 | 2022 | |
| Phadia US INC. | $27.70 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $26.58 | 2022 | |
| Viatris Specialty LLC | $24.83 | 2025 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.79 | 2025 | Caplyta |
| Lundbeck LLC | $18.01 | 2025 | Rexulti |
| Aimmune Therapeutics, INC. | $15.99 | 2024 | |
| Paratek Pharmaceuticals, INC. | $14.96 | 2021 | |
| Hologic Sales and Service, LLC | $13.35 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.82 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Mabry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.